Tumor‑infiltrating CD8⁺ T cells as a biomarker for chemotherapy efficacy in unresectable hepatocellular carcinoma.

ABSTRACT: Atezolizumab plus bevacizumab and lenvatinib are approved frontline therapies for advanced hepatocellular carcinoma (HCC). Patients with advanced HCC continue to have a poor prognosis despite these therapeutic choices. Previous studies have reported CD8⁺ tumor-infiltrating lymphocytes (TILs) as a biomarker to predict responsiveness to systemic chemotherapy. The present study investigated whether evaluating CD8⁺ TILs by immunohistochemistry staining of liver tumor biopsy tissues could help predict the response of patients with HCC to atezolizumab plus bevacizumab and lenvatinib. In total, 39 patients with HCC who underwent liver tumor biopsy were classified into high and low CD8⁺ TILs groups and were then divided by therapy type. The clinical responses to tr

SUBMITTER: Kuwano A 

PROVIDER: S-EPMC10189850 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature